FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948029887> ?p ?o ?g. }

• W2948029887 abstract "Secondary bacterial lung infection by Streptococcus pneumoniae (S. pneumoniae) poses a serious health concern, especially in developing countries. We posit that the emergence of multiantibiotic-resistant strains will jeopardize current treatments in these regions. Deaths arising from secondary infections are more often associated with acute lung injury, a common consequence of hypercytokinemia, than with the infection per se Given that secondary bacterial pneumonia often has a poor prognosis, newer approaches to improve treatment outcomes are urgently needed to reduce the high levels of morbidity and mortality. Using a sequential dual-infection mouse model of secondary bacterial lung infection, we show that host-directed therapy via immunoneutralization of the angiopoietin-like 4 c-isoform (cANGPTL4) reduced pulmonary edema and damage in infected mice. RNA sequencing analysis revealed that anti-cANGPTL4 treatment improved immune and coagulation functions and reduced internal bleeding and edema. Importantly, anti-cANGPTL4 antibody, when used concurrently with either conventional antibiotics or antipneumolysin antibody, prolonged the median survival of mice compared to monotherapy. Anti-cANGPTL4 treatment enhanced immune cell phagocytosis of bacteria while restricting excessive inflammation. This modification of immune responses improved the disease outcomes of secondary pneumococcal pneumonia. Taken together, our study emphasizes that host-directed therapeutic strategies are viable adjuncts to standard antimicrobial treatments.IMPORTANCE Despite extensive global efforts, secondary bacterial pneumonia still represents a major cause of death in developing countries and is an important cause of long-term functional disability arising from lung tissue damage. Newer approaches to improving treatment outcomes are needed to reduce the significant morbidity and mortality caused by infectious diseases. Our study, using an experimental mouse model of secondary S. pneumoniae infection, shows that a multimodal treatment that concurrently targets host and pathogen factors improved lung tissue integrity and extended the median survival time of infected mice. The immunoneutralization of host protein cANGPTL4 reduced the severity of pulmonary edema and damage. We show that host-directed therapeutic strategies as well as neutralizing antibodies against pathogen virulence factors are viable adjuncts to standard antimicrobial treatments such as antibiotics. In view of their different modes of action compared to antibiotics, concurrent immunotherapies using antibodies are potentially efficacious against secondary pneumococcal pneumonia caused by antibiotic-resistant pathogens." @default.
• W2948029887 created "2019-06-14" @default.
• W2948029887 creator A5003615630 @default.
• W2948029887 creator A5007960024 @default.
• W2948029887 creator A5016606654 @default.
• W2948029887 creator A5018932636 @default.
• W2948029887 creator A5026787939 @default.
• W2948029887 creator A5029435621 @default.
• W2948029887 creator A5033528740 @default.
• W2948029887 creator A5034512981 @default.
• W2948029887 creator A5059974201 @default.
• W2948029887 creator A5062504863 @default.
• W2948029887 creator A5064564309 @default.
• W2948029887 creator A5069249242 @default.
• W2948029887 creator A5069266409 @default.
• W2948029887 creator A5070048995 @default.
• W2948029887 creator A5071159100 @default.
• W2948029887 creator A5077944210 @default.
• W2948029887 creator A5081303849 @default.
• W2948029887 creator A5086344364 @default.
• W2948029887 creator A5091066668 @default.
• W2948029887 date "2019-06-25" @default.
• W2948029887 modified "2023-10-02" @default.
• W2948029887 title "Antibody Treatment against Angiopoietin-Like 4 Reduces Pulmonary Edema and Injury in Secondary Pneumococcal Pneumonia" @default.
• W2948029887 cites W144317117 @default.
• W2948029887 cites W1522834891 @default.
• W2948029887 cites W1606573317 @default.
• W2948029887 cites W1635544817 @default.
• W2948029887 cites W1637747050 @default.
• W2948029887 cites W1661717153 @default.
• W2948029887 cites W1966757591 @default.
• W2948029887 cites W1977142289 @default.
• W2948029887 cites W1978465166 @default.
• W2948029887 cites W1979849055 @default.
• W2948029887 cites W1993368552 @default.
• W2948029887 cites W1999686948 @default.
• W2948029887 cites W2001484558 @default.
• W2948029887 cites W2003397002 @default.
• W2948029887 cites W2005388865 @default.
• W2948029887 cites W2010021083 @default.
• W2948029887 cites W2014317349 @default.
• W2948029887 cites W2023064918 @default.
• W2948029887 cites W2028117310 @default.
• W2948029887 cites W2034279668 @default.
• W2948029887 cites W2034285706 @default.
• W2948029887 cites W2035868732 @default.
• W2948029887 cites W2039782308 @default.
• W2948029887 cites W2049194781 @default.
• W2948029887 cites W2056257151 @default.
• W2948029887 cites W2057253189 @default.
• W2948029887 cites W2061123791 @default.
• W2948029887 cites W2063305823 @default.
• W2948029887 cites W2073234751 @default.
• W2948029887 cites W2075156841 @default.
• W2948029887 cites W2079039203 @default.
• W2948029887 cites W2083309263 @default.
• W2948029887 cites W2085780588 @default.
• W2948029887 cites W2089483990 @default.
• W2948029887 cites W2095589751 @default.
• W2948029887 cites W2099926545 @default.
• W2948029887 cites W2101306209 @default.
• W2948029887 cites W2102978702 @default.
• W2948029887 cites W2103272277 @default.
• W2948029887 cites W2109812222 @default.
• W2948029887 cites W2119531132 @default.
• W2948029887 cites W2122758441 @default.
• W2948029887 cites W2126463051 @default.
• W2948029887 cites W2130553813 @default.
• W2948029887 cites W2130572697 @default.
• W2948029887 cites W2132771934 @default.
• W2948029887 cites W2137313784 @default.
• W2948029887 cites W2137536958 @default.
• W2948029887 cites W2141963879 @default.
• W2948029887 cites W2151295474 @default.
• W2948029887 cites W2155425126 @default.
• W2948029887 cites W2161328469 @default.
• W2948029887 cites W2165760175 @default.
• W2948029887 cites W2179438025 @default.
• W2948029887 cites W2201568507 @default.
• W2948029887 cites W2270693848 @default.
• W2948029887 cites W2320618369 @default.
• W2948029887 cites W2333405172 @default.
• W2948029887 cites W2531408947 @default.
• W2948029887 cites W586267484 @default.
• W2948029887 cites W1973946301 @default.
• W2948029887 doi "https://doi.org/10.1128/mbio.02469-18" @default.
• W2948029887 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6550533" @default.
• W2948029887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31164474" @default.
• W2948029887 hasPublicationYear "2019" @default.
• W2948029887 type Work @default.
• W2948029887 sameAs 2948029887 @default.
• W2948029887 citedByCount "18" @default.
• W2948029887 countsByYear W29480298872019 @default.
• W2948029887 countsByYear W29480298872020 @default.
• W2948029887 countsByYear W29480298872021 @default.
• W2948029887 countsByYear W29480298872022 @default.
• W2948029887 countsByYear W29480298872023 @default.
• W2948029887 crossrefType "journal-article" @default.
• W2948029887 hasAuthorship W2948029887A5003615630 @default.
• W2948029887 hasAuthorship W2948029887A5007960024 @default.

• next